Sangamo Therapeutics SGMO Stock Momentum Analysis Sangamo Therapeutics posts 797 downside EPS miss SFM Sprouts beats Q4 2025 earnings per share estimates shares rise two percent during todays trading Goldman Sachs Group Inc GS Alternatives Division Leads 60M Series C Funding for Workplace Fintech Kashable Expanding Inclusive Growth Investment Portfolio